Ustekinumab-aekn

Drug Overview

In the rapidly evolving landscape of Immunology, the introduction of biosimilar medications has opened new doors for patient access to life-changing therapies. Wezlana is a highly sophisticated Biologic medication that serves as the first FDA-approved interchangeable biosimilar to Stelara (ustekinumab). As a premier Immunomodulator, it is designed to address the root causes of chronic inflammation by targeting specific signaling proteins in the immune system. We understand that managing an autoimmune condition requires not only clinical precision but also an empathetic approach to long-term care; Wezlana represents a major step forward in making Targeted Therapy more accessible for patients worldwide.

Wezlana belongs to the drug class known as Interleukin Inhibitors. It is a human Monoclonal Antibody that has been rigorously tested to ensure it provides the same therapeutic benefits, safety, and quality as its reference product. By acting as an “interchangeable” biosimilar, it meets additional high standards that allow pharmacists to substitute it for the reference product, depending on local regulations, to help lower healthcare costs without compromising patient outcomes.

• Generic Name: Ustekinumab-aauz
• US Brand Name: Wezlana
• Route of Administration: Initial intravenous (IV) infusion for certain conditions, followed by maintenance via subcutaneous (SC) injection.
• FDA Approval Status: FDA-approved (October 2023) as an interchangeable biosimilar for the treatment of multiple inflammatory conditions.
  
  Our medical hospital provides expert insights on ustekinumab-aekn, a trusted Interleukin Inhibitor prescribed for Selarsdi (Ustekinumab biosimilar). Find out how this medication improves long-term patient outcomes.

What Is It and How Does It Work? (Mechanism of Action)

To understand how Wezlana functions as a Targeted Therapy, one must examine the complex communication network of the immune system. In many autoimmune diseases, the body produces an excess of cytokines—specialized proteins that act as messengers. Two specific cytokines, Interleukin-12 (IL-12) and Interleukin-23 (IL-23), are the primary drivers of inflammation in the skin, joints, and gastrointestinal tract.

At the molecular and cellular level, Wezlana exerts its effect through selective cytokine inhibition:

1. Targeting the p40 Subunit: Both IL-12 and IL-23 cytokines share a common protein structure known as the p40 subunit. Wezlana is a Monoclonal Antibody engineered to bind specifically and with high affinity to this p40 subunit.
2. Blocking Receptor Binding: By latching onto the p40 subunit, Wezlana prevents IL-12 and IL-23 from binding to their respective IL-12Rβ1 receptor proteins found on the surface of immune cells, such as T-cells and Natural Killer (NK) cells.
3. Inhibition of the Th1 and Th17 Pathways: By blocking these receptors, the drug prevents the activation and differentiation of Th1 and Th17 cells. These specific T-cells are the “factories” that produce secondary inflammatory markers like Interferon-gamma (IFNγ) and Interleukin-17 (IL-17).
4. Interference with Signaling: This blockade effectively stops the JAK-STAT signaling pathway interference within the immune cells. Without this signal, the cell cannot “turn on” the genes that cause tissue damage, swelling, and the rapid skin cell turnover seen in psoriasis.
5. Restoring Immune Balance: Rather than suppressing the entire immune system, this Immunomodulator precisely targets these specific pathways, allowing the body to reduce systemic inflammation while maintaining other essential immune functions.

FDA-Approved Clinical Indications

As a comprehensive Targeted Therapy, Wezlana is approved for use in several different areas of Immunology where IL-12 and IL-23 play a central role.

Primary Indication

• Biosimilar Utilization: Wezlana is primarily indicated as an interchangeable biosimilar to ustekinumab for the management of chronic inflammatory diseases where the p40 subunit pathway is overactive.

Other Approved & Off-Label Uses

• Plaque Psoriasis (Ps): For adult and pediatric patients (6 years and older) with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
• Psoriatic Arthritis (PsA): For adult patients with active psoriatic arthritis.
• Crohn’s Disease (CD): For adult patients with moderately to severely active Crohn’s disease.
• Ulcerative Colitis (UC): For adult patients with moderately to severely active ulcerative colitis.

Primary Immunology Indications:

• Systemic Cytokine Modulation: Normalizing the IL-12 and IL-23 levels to prevent the immune system from attacking the lining of the gut or the layers of the skin.
• Mucosal Healing: Promoting the repair of the intestinal wall in patients with IBD (Crohn’s and UC).
• Keratinocyte Regulation: Reducing the speed of skin cell production to eliminate thick, scaly psoriasis plaques.

Dosage and Administration Protocols

Dosing for Wezlana is highly personalized, often involving a weight-based induction phase to ensure the Biologic reaches therapeutic levels quickly in the bloodstream.

Dose Adjustments and Special Populations:

• Weight Threshold: For adult psoriasis, patients weighing more than 100 kg (220 lbs) typically require the 90 mg dose to achieve the same efficacy as the 45 mg dose in lighter patients.
• Pediatric Transition: Dosing for children 6 years and older is strictly weight-dependent and must be recalculated as the child grows.
• Elderly Patients: While no specific dose adjustment is usually required, clinicians should monitor for increased sensitivity to infections.
• Infusion Timing: For Crohn’s and UC, the initial dose is a one-time IV infusion. All subsequent doses are given as a subcutaneous injection, which can often be self-administered at home after proper training.

Clinical Efficacy and Research Results

The approval of Wezlana as an interchangeable biologic is supported by comparative trials (2020–2026) showing it matches the reference product in efficacy and safety, with no loss of effect when switching.

In plaque psoriasis, ~67%–73% of patients achieved PASI 75 within 12 weeks. In psoriatic arthritis, significant ACR20 and ACR50 responses reflect reduced joint symptoms.

Updated research (2024–2025) shows reduced CRP and ESR with IL-12/23 inhibition and strong rates of steroid-free remission in Crohn’s disease, supporting long-term inflammatory control.

Safety Profile and Side Effects

While Wezlana is highly effective, it does modify the immune response, which requires careful medical monitoring.

• Black Box Warning: Currently, Wezlana does not have a Black Box Warning. However, it is closely monitored for the risk of serious infections.

Common Side Effects (>10%)

• Nasopharyngitis: Common cold-like symptoms and upper respiratory tract infections.
• Headache: Usually mild and occurring shortly after the dose.
• Fatigue: A general sense of tiredness.
• Injection Site Reactions: Redness, swelling, or itching where the shot was given.

Serious Adverse Events

• Opportunistic Infections: Increased risk of serious bacterial, fungal, or viral infections (including Tuberculosis).
• Malignancies: A rare but theoretical risk of skin and non-skin cancers associated with long-term immunomodulation.
• Posterior Reversible Encephalopathy Syndrome (PRES): A very rare neurological condition involving headache and seizures.
• Non-Infectious Pneumonia: Rare instances of lung inflammation that require immediate cessation of the drug.

Management Strategies

Clinical protocols include “pre-medication” screening. All patients must be screened for Tuberculosis (TB) before starting the medication. If a serious infection occurs, a “wash-out” period is mandatory where the drug is withheld until the infection is cleared. Patients are also encouraged to undergo periodic skin exams to monitor for any changes.

Research Areas

Direct Clinical Connections:

In the most recent research (2025–2026), scientists are investigating the drug’s impact on regulatory T-cell (Treg) expansion. By potentially increasing these “peacekeeper” cells, the therapy may help re-train the immune system for longer-lasting stability. There is also significant focus on autoantibody suppression in multi-organ diseases like Lupus.

Generalization:

The development of Wezlana has significantly advanced the field of Biosimilars. Active clinical trials are currently evaluating the use of the IL-12/23 pathway in preventing the “cytokine storm” associated with severe systemic hyper-inflammation. Furthermore, research is focusing on Novel Delivery Systems, such as more concentrated formulas that allow for smaller injection volumes and improved autoinjectors for patients with limited dexterity.

Severe Disease & Multi-Organ Involvement:

Precision Immunology research is now exploring Wezlana’s efficacy in preventing systemic damage, such as interstitial lung disease or cardiovascular inflammation, which are often “hidden” complications of chronic psoriasis. Researchers are working to identify genetic biomarkers that can predict which patients will have a “super-response” to this specific Targeted Therapy.

Disclaimer: 

This topic should be treated as evidence-based but not definitive. Statements implying proven Treg expansion, cytokine-storm prevention, hidden organ protection, or accurate prediction of a “super-response” should be interpreted cautiously unless supported by direct clinical evidence. Wezlana is an important biosimilar IL-12/23 therapy, but many broader precision-immunology and delivery-related claims remain investigational.

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: QuantiFERON-TB Gold test for Tuberculosis and screening for Hepatitis B and C.
• Organ Function: Complete Blood Count (CBC) and Liver Function Tests (LFTs).
• Screening: A full review of vaccination history is essential. Patients should receive any necessary inactivated vaccines before starting therapy.
• Specialized Testing: Baseline inflammatory markers (CRP/ESR) to track the drug’s progress.

Monitoring and Precautions

• Vigilance: Monitoring for signs of infection (fever, cough, or flu-like symptoms) and “loss of response” which could indicate the formation of anti-drug antibodies.
• Lifestyle: We recommend an anti-inflammatory diet and stress management techniques to support the Immunomodulator‘s effects. Sun protection is vital for patients with photosensitive conditions.
• “Do’s and Don’ts” list:
  • DO keep your scheduled blood work appointments.
  • DO inform your doctor of any recent travel to areas where TB is common.
  • DO stay up to date on your annual flu shot (inactivated).
  • DON’T receive any “live” vaccines (like the shingles or MMR vaccine) while on this drug.
  • DON’T ignore a persistent cough or skin changes.

Legal Disclaimer

The medical information provided in this guide is for educational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Wezlana is a potent Biologic and should only be used under the direct supervision of a qualified healthcare professional. Always seek the advice of your physician or a specialist immunologist regarding any medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. In case of a medical emergency, contact your local emergency services immediately.